In 2014, the FDA approved 41 novel new drugs, many more than its yearly average of 25 from 2005 through 2013.

In 2014, the FDA approved 41 novel new drugs, the most since the agency approved 53 in 1996, and ahead of its yearly average of 25 from 2005 through 2013. Nine of the 41 new drugs were approved for the treatment of cancer, and four of those were considered to be first-in-class agents: blinatumomab (Blincyto; Amgen), pembrolizumab (Keytruda; Merck), olaparib (Lynparza; AstraZeneca), and idelalisib (Zydelig; Gilead). [Source: FDA]

In 2014, the FDA approved 41 novel new drugs, the most since the agency approved 53 in 1996, and ahead of its yearly average of 25 from 2005 through 2013. Nine of the 41 new drugs were approved for the treatment of cancer, and four of those were considered to be first-in-class agents: blinatumomab (Blincyto; Amgen), pembrolizumab (Keytruda; Merck), olaparib (Lynparza; AstraZeneca), and idelalisib (Zydelig; Gilead). [Source: FDA]

Close modal

For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.